Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: The meta-analysis by Dr LaRosa
and colleagues1 demonstrated that statins
reduce the risk of coronary heart disease for all patients regardless of sex
or age. However, LaRosa et al did not distinguish between primary and secondary
prevention. Since primary prevention potentially includes a large segment
of the population, it is important to examine these data separately. The West
of Scotland Coronary Prevention Study (WOSCOPS) trial2
showed that primary prevention is effective for men aged 45 to 64 years, and
the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)3 extended this benefit to 73 years. Women were not
included in the WOSCOPS trial, and the analysis of LaRosa et al showed a nonsignificant
effect for women in the AFCAPS/TexCAPS trial.
Clemenson ND. Statins and Risk of Coronary Heart Disease. JAMA. 2000;283(22):2935. doi:10.1001/jama.283.22.2931